Literature DB >> 12120441

Cutaneous manifestations of Epstein-Barr virus infection.

Nneka I Ikediobi1, Stephen K Tyring.   

Abstract

The most common cutaneous manifestations of EBV include IM, OHL, and cutaneous lymphoproliferative disorders. Infectious mononucleosis is a self-limited manifestation of acute EBV infection. The transient rash that occurs quite commonly in patients with IM who have received antibiotic therapy is an erythematous, maculopapular eruption, usually located on the trunk and upper extremities. Oral hairy leukoplakia occurs in immunosuppressed HIV-positive and HIV-negative individuals. In HIV-positive individuals, it serves as an indicator of disease severity and rapid progression to AIDS. The presence of OHL in an individual should prompt the clinician to perform a through history-taking and investigation of immune status. Cutaneous lymphoproliferative disorders associated with EBV occur in individuals with congenital or acquired immunodeficiency syndromes.

Entities:  

Mesh:

Year:  2002        PMID: 12120441     DOI: 10.1016/s0733-8635(01)00014-6

Source DB:  PubMed          Journal:  Dermatol Clin        ISSN: 0733-8635            Impact factor:   3.478


  4 in total

1.  Genitourinary manifestations of epstein-barr virus infections.

Authors:  Randi Leigh; Paul Nyirjesy
Journal:  Curr Infect Dis Rep       Date:  2009-11       Impact factor: 3.725

Review 2.  [Frequent and rare dermatological diseases in HIV patients].

Authors:  U R Hengge; R Mota; A Marini
Journal:  Hautarzt       Date:  2006-11       Impact factor: 0.751

Review 3.  Dermatological aspects of SARS-CoV-2 infection: mechanisms and manifestations.

Authors:  Myriam Garduño-Soto; Jose Alberto Choreño-Parra; Jorge Cazarin-Barrientos
Journal:  Arch Dermatol Res       Date:  2020-11-06       Impact factor: 3.017

4.  False positive immunoglobulin m antibody to cytomegalovirus in child with infectious mononucleosis caused by epstein-barr virus infection.

Authors:  Jee Min Park; Jae Il Shin; Jae Seung Lee; Young Ho Jang; Sung Hun Kim; Kang Hyuk Lee; Chang Hoon Lee
Journal:  Yonsei Med J       Date:  2009-10-21       Impact factor: 2.759

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.